Department of Bioscience and Laboratory Medicine, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori 036-8564, Japan.
Department of Medical Technology, Hirosaki University School of Health Sciences, Hirosaki, Aomori 036-8564, Japan.
Medicina (Kaunas). 2020 Feb 12;56(2):72. doi: 10.3390/medicina56020072.
B-lymphoma Mo-MLV insertion region 1 (Bmi-1) is a stem cell factor that is overexpressed in various human cancer tissues. It has been implicated in cancer cell proliferation, cell invasion, distant metastasis, and chemosensitivity, and is associated with patient survival. Several reports have also identified Bmi-1 protein overexpression in endometrial carcinoma; however, the relationship between Bmi-1 expression and its significance as a clinicopathological parameter is still insufficiently understood. Accordingly, the present study aimed to clarify whether immunohistochemical staining for Bmi-1 in human endometrial carcinoma and normal endometrial tissues can be used as a prognostic and cell proliferation marker. Bmi-1 expression was assessed in endometrioid carcinoma (grade 1-3) and normal endometrial tissues (in the proliferative and secretory phases) by immunohistochemistry; protein expression was evaluated using the nuclear labeling index (%) in the hot spot. Furthermore, we examined other independent prognostic and proliferation markers, including the protein levels of Ki-67, p53, and cyclin A utilizing semi-serial sections of endometrial carcinoma tissues. The expression of the Bmi-1 protein was significantly higher in all grades of endometrial carcinoma than in the secretory phase of normal tissues. Moreover, Bmi-1 levels tended to be higher in G2 and G3 tissues than in G1 tissue, without reaching significance. Bmi-1 expression showed no notable differences among International Federation of Gynecology and Obstetrics (FIGO) stages in endometrial carcinoma. Furthermore, we observed a significant positive relationship between Bmi-1 and Ki-67, cyclin A, or p53 by Spearman's rank correlation test, implying that high Bmi-1 expression can be an independent prognostic marker in endometrial carcinoma. Our study suggests that Bmi-1 levels in endometrial carcinoma tissues may be useful as a reliable proliferation and prognostic biomarker. Recently, the promise of anti-Bmi-1 strategies for the treatment of endometrial carcinoma has been detected. Our results provide fundamental data regarding this anti-Bmi-1 strategy.
B 细胞淋巴瘤 Moloney 白血病病毒插入区 1（Bmi-1）是一种在各种人类癌症组织中过度表达的干细胞因子。它被认为与癌细胞增殖、细胞侵袭、远处转移和化疗敏感性有关，并与患者的生存有关。一些报道还发现子宫内膜癌中存在 Bmi-1 蛋白过表达；然而，Bmi-1 表达与其作为临床病理参数的意义之间的关系仍了解不足。因此，本研究旨在阐明人子宫内膜癌和正常子宫内膜组织中 Bmi-1 的免疫组织化学染色是否可用作预后和细胞增殖标志物。
通过免疫组织化学评估子宫内膜样癌（1-3 级）和正常子宫内膜组织（增殖期和分泌期）中的 Bmi-1 表达；在热点处使用核标记指数（%）评估蛋白表达。此外，我们利用子宫内膜癌组织的半系列切片检查了其他独立的预后和增殖标志物，包括 Ki-67、p53 和细胞周期蛋白 A 的蛋白水平。
Bmi-1 蛋白的表达在所有分级的子宫内膜癌中均明显高于正常组织的分泌期。此外，Bmi-1 水平在 G2 和 G3 组织中趋于高于 G1 组织，但无显著差异。Bmi-1 表达在子宫内膜癌的国际妇产科联合会（FIGO）分期中无明显差异。此外，我们通过 Spearman 等级相关检验观察到 Bmi-1 与 Ki-67、细胞周期蛋白 A 或 p53 之间存在显著正相关，这表明高 Bmi-1 表达可能是子宫内膜癌的独立预后标志物。
我们的研究表明，子宫内膜癌组织中的 Bmi-1 水平可能是一种可靠的增殖和预后生物标志物。最近，已经检测到针对 Bmi-1 的抗治疗策略在治疗子宫内膜癌方面的前景。我们的研究结果为此提供了基础数据。
